Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Core Insights - Revolution Medicines, Inc. reported positive updates from its daraxonrasib Phase 1 trials, leading to an increase in stock price [1][7] Group 1: Clinical Trial Results - In the Phase 1 trial for second-line (2L) metastatic pancreatic ductal adenocarcinoma (PDAC), daraxonrasib showed an objective response rate (ORR) of 35% for RAS G12X mutation patients and 29% for any RAS mutation patients [1] - The disease control rate (DCR) was 92% for RAS G12X mutation patients and 95% for any RAS mutation patients [2] - Median progression-free survival (PFS) was reported at 8.5 months for RAS G12X mutation patients and 8.1 months for any RAS mutation patients, while median overall survival (OS) was 13.1 months and 15.6 months respectively [2] Group 2: Safety and Tolerability - Daraxonrasib 300 mg QD was generally well tolerated in 2L+ patients with RAS mutant PDAC (n=83), with no new safety signals identified [3] - The safety profile for daraxonrasib as a first-line (1L) treatment was consistent with previous findings, with a mean dose intensity of 85% [5] Group 3: Future Trials and Developments - The ongoing Phase 3 trial, RASolute 302, for daraxonrasib monotherapy as a 2L treatment for metastatic PDAC is expected to complete global enrollment this year, with data readout anticipated in 2026 [3] - A new global, randomized Phase 3 trial, RASolute 303, for patients with 1L metastatic PDAC is planned to be initiated in Q4 2025 [6] Group 4: Analyst Ratings and Stock Performance - Wells Fargo, Wedbush, and Needham have all maintained positive ratings on Revolution Medicines, with price forecasts raised to $70, $77, and $66 respectively [7] - RVMD stock increased by 12.34% to $45.44 following the trial updates [7]